EP0749313A4 - Method for treating 5ht 2b receptor related conditions - Google Patents
Method for treating 5ht 2b receptor related conditionsInfo
- Publication number
- EP0749313A4 EP0749313A4 EP95914014A EP95914014A EP0749313A4 EP 0749313 A4 EP0749313 A4 EP 0749313A4 EP 95914014 A EP95914014 A EP 95914014A EP 95914014 A EP95914014 A EP 95914014A EP 0749313 A4 EP0749313 A4 EP 0749313A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treating
- related conditions
- receptor related
- receptor
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US380566 | 1989-07-14 | ||
US380565 | 1989-07-14 | ||
US21262294A | 1994-03-11 | 1994-03-11 | |
US08/380,566 US5688807A (en) | 1994-03-11 | 1995-02-06 | Method for treating 5HT2B receptor related conditions |
US08/380,565 US5663178A (en) | 1995-02-06 | 1995-02-06 | Tetrahydro-beta carbolines |
PCT/US1995/003099 WO1995024200A1 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht2b receptor related conditions |
US212622 | 1998-12-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0749313A1 EP0749313A1 (en) | 1996-12-27 |
EP0749313A4 true EP0749313A4 (en) | 2001-10-24 |
Family
ID=27395770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95914014A Withdrawn EP0749313A4 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht 2b receptor related conditions |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0749313A4 (en) |
JP (1) | JPH09510216A (en) |
CN (1) | CN1148340A (en) |
AU (1) | AU679635B2 (en) |
CA (1) | CA2185236A1 (en) |
CZ (1) | CZ264996A3 (en) |
FI (1) | FI963571A (en) |
HU (1) | HUT75522A (en) |
IL (1) | IL112958A0 (en) |
NO (1) | NO963785L (en) |
WO (1) | WO1995024200A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
JPH11503757A (en) * | 1995-04-18 | 1999-03-30 | イーライ・リリー・アンド・カンパニー | Use of ergoline compounds that produce physiological and pathological functions at 5-HT (7) receptors |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
CN1218368A (en) * | 1996-03-15 | 1999-06-02 | 伊莱利利公司 | Method for treating common cold or allergic rhinitis |
US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
DE69729211T2 (en) * | 1996-03-25 | 2005-05-04 | Eli Lilly And Co., Indianapolis | TETRAHYDRO-BETA CARBOLINE COMPOUNDS |
US5886003A (en) * | 1996-03-25 | 1999-03-23 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of venomous bites and stings |
EA000769B1 (en) * | 1996-03-25 | 2000-04-24 | Эли Лилли Энд Компани | Method for treating migraine pain |
WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
AU777594B2 (en) * | 1999-05-24 | 2004-10-21 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
US20050065202A1 (en) * | 2003-05-09 | 2005-03-24 | Vidal Ramon Merce | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
KR20080044273A (en) | 2005-08-08 | 2008-05-20 | 아스텔라스세이야쿠 가부시키가이샤 | Acylguanidine derivative or salt thereof |
CN101384549B (en) * | 2006-02-20 | 2011-04-13 | 安斯泰来制药株式会社 | Pyrrole derivative or salt thereof |
BRPI0906244A2 (en) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Compound, pharmaceutical composition, method for treating a cognitive, psychotic, neurotransmitter mediated disorder or a neuronal disorder in an individual, use of a compound and kit |
EP2386546B1 (en) | 2008-11-21 | 2015-08-19 | RaQualia Pharma Inc | Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity |
TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
US20130137705A1 (en) * | 2009-09-23 | 2013-05-30 | Sarvajit Chakravarty | Pyrido[3,4-b]indoles and methods of use |
CN102724875B (en) | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | Pyrido[3,4-b]indoles and methods of use |
KR102401841B1 (en) | 2016-04-01 | 2022-05-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | estrogen receptor modulators |
WO2020176597A1 (en) * | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
AU2020326691A1 (en) | 2019-08-06 | 2022-03-03 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
CN116514824A (en) * | 2022-01-29 | 2023-08-01 | 上海科技大学 | Tri-ring compound, preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
US4731358A (en) * | 1982-10-29 | 1988-03-15 | Schering Aktiengesellschaft | β-carbolines and their use as tranquilizers |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
EP0620222A2 (en) * | 1993-04-14 | 1994-10-19 | Eli Lilly And Company | Tetrahydro-beta-carbolines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4520024A (en) * | 1983-02-11 | 1985-05-28 | Eli Lilly And Company | Method of selectively blocking peripheral vascular serotonergic receptors |
-
1995
- 1995-03-10 AU AU21186/95A patent/AU679635B2/en not_active Ceased
- 1995-03-10 CZ CZ962649A patent/CZ264996A3/en unknown
- 1995-03-10 IL IL11295895A patent/IL112958A0/en unknown
- 1995-03-10 CN CN95193029A patent/CN1148340A/en active Pending
- 1995-03-10 EP EP95914014A patent/EP0749313A4/en not_active Withdrawn
- 1995-03-10 CA CA002185236A patent/CA2185236A1/en not_active Abandoned
- 1995-03-10 JP JP7523692A patent/JPH09510216A/en active Pending
- 1995-03-10 HU HU9602482A patent/HUT75522A/en unknown
- 1995-03-10 WO PCT/US1995/003099 patent/WO1995024200A1/en not_active Application Discontinuation
-
1996
- 1996-09-10 NO NO963785A patent/NO963785L/en unknown
- 1996-09-10 FI FI963571A patent/FI963571A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
US4731358A (en) * | 1982-10-29 | 1988-03-15 | Schering Aktiengesellschaft | β-carbolines and their use as tranquilizers |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
EP0620222A2 (en) * | 1993-04-14 | 1994-10-19 | Eli Lilly And Company | Tetrahydro-beta-carbolines |
Non-Patent Citations (6)
Title |
---|
AUDIA, J. E. ET AL.: "Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B contractile receptor in the rat stomach fundus", J. MED. CHEM., vol. 39, 1996, pages 2773 - 2780, XP002167539 * |
GLENNON, R. A.: "Central Serotonin Receptors as Targets for Drug Research", J. MED. CHEM., vol. 30, 1987, pages 1 - 12, XP002167538 * |
MARTIN G R ET AL: "RECEPTORS FOR 5-HYDROXYTRYPTAMINE: CURRENT PERSPECTIVES ON CLASSIFICATION AND NOMENCLATURE", NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, vol. 33, no. 3/04, 1 March 1994 (1994-03-01), pages 261 - 273, XP002037183, ISSN: 0028-3908 * |
ONDA, M.; KAWANISHI, M.: "Analogs of Rauwolfia Alkaloids", J. PHARM. SOC. JPN., vol. 76, 1956, pages 966 - 968, XP000985848 * |
See also references of WO9524200A1 * |
SPÄTH, E. ET AL: "SYNTHESEN VON 4-CARBOLINEN", CHEMISCHE BERICHTE,XX,XX, vol. 120, 18 July 1930 (1930-07-18), pages 2102 - 2111, XP000917524, ISSN: 0009-2940 * |
Also Published As
Publication number | Publication date |
---|---|
NO963785L (en) | 1996-11-01 |
NO963785D0 (en) | 1996-09-10 |
AU2118695A (en) | 1995-09-25 |
HU9602482D0 (en) | 1996-11-28 |
EP0749313A1 (en) | 1996-12-27 |
AU679635B2 (en) | 1997-07-03 |
FI963571A0 (en) | 1996-09-10 |
JPH09510216A (en) | 1997-10-14 |
CZ264996A3 (en) | 1998-01-14 |
WO1995024200A1 (en) | 1995-09-14 |
FI963571A (en) | 1996-11-08 |
CN1148340A (en) | 1997-04-23 |
HUT75522A (en) | 1997-05-28 |
CA2185236A1 (en) | 1995-09-14 |
IL112958A0 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0749313A4 (en) | Method for treating 5ht 2b receptor related conditions | |
IL126203A0 (en) | Method for treating pain | |
EP0906104A4 (en) | Method for treating pain | |
AU3813397A (en) | Apparatus for treating chondromalicia | |
IL115784A0 (en) | Method for forming emulsions | |
EP1110078A4 (en) | Adaptive lighting system and method for machine vision apparatus | |
SG50018A1 (en) | Method for developing treatment | |
ZA959168B (en) | Method for treating anxiety | |
ZA952022B (en) | Method for treating 5HT2B receptor related conditions | |
IL126759A0 (en) | Method for treating inflammation | |
IL113395A0 (en) | Method and apparatus for providing secure communications | |
IL126064A0 (en) | Method for treating pain | |
IL125031A0 (en) | Method for treating depression | |
IL130531A0 (en) | Method for treating glaucoma | |
AU7726396A (en) | Method for treating anxiety | |
AU7674796A (en) | Method for treating anxiety | |
IL124786A0 (en) | Method for treating pain | |
EP0769904A4 (en) | Method for treating anxiety | |
IL126657A0 (en) | Method for treating or preventing ischemia-reperfusion injury | |
EP0783304A4 (en) | Method for treating anxiety | |
ZA971899B (en) | Method for treating insomnia | |
AP9701121A0 (en) | Method for prearing streptogramines | |
GB9404964D0 (en) | Method and apparatus for flushing | |
HU9501515D0 (en) | Boundary-stone, method for place out and apparatus for making boundary-stones | |
IL121223A0 (en) | Method for treating 5HT2b receptor related conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960911 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 960911;SI PAYMENT 960911 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 471/04 A, 7C 07D 209/16 B, 7C 07D 457/04 B, 7C 07D 457/06 B, 7C 07D 241/04 B, 7C 07D 403/12 B, 7C 07D 261/08 B, 7A 61K 31/551 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010911 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011203 |